• Product name
    Anti-IRAK4 antibody [Y279]
    See all IRAK4 primary antibodies
  • Description
    Rabbit monoclonal [Y279] to IRAK4
  • Host species
  • Tested applications
    Suitable for: ICC, IHC-P, WB, Flow Cyt, ICC/IFmore details
    Unsuitable for: IP
  • Species reactivity
    Reacts with: Human
  • Immunogen

    Synthetic peptide within Human IRAK4 aa 1-100 (N terminal). The exact sequence is proprietary.

  • Positive control
    • Jurkat cell lysate. IHC-P: FFPE human spleen tissue sections.
  • General notes

    Mouse, Rat: We have preliminary internal testing data to indicate this antibody may not react with these species. Please contact us for more information.


    Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMab® patents

    This product is a recombinant rabbit monoclonal antibody.



Our Abpromise guarantee covers the use of ab32511 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
ICC 1/50 - 1/100.
IHC-P Use a concentration of 1 µg/ml. Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol.
WB 1/1000 - 1/10000. Detects a band of approximately 52 kDa.
Flow Cyt Use at an assay dependent concentration.
ICC/IF Use at an assay dependent concentration.
  • Application notes
    Is unsuitable for IP.
  • Target

    • Function
      Required for the efficient recruitment of IRAK1 to the IL-1 receptor complex following IL-1 engagement, triggering intracellular signaling cascades leading to transcriptional up-regulation and mRNA stabilization. Phosphorylates IRAK1.
    • Involvement in disease
      Defects in IRAK4 are the cause of recurrent isolated invasive pneumococcal disease type 1 (IPD1) [MIM:610799]. Recurrent invasive pneumococcal disease (IPD) is defined as two episodes of IPD occurring at least 1 month apart, whether caused by the same or different serotypes or strains. Recurrent IPD occurs in at least 2% of patients in most series, making IPD the most important known risk factor for subsequent IPD.
      Defects in IRAK4 are the cause of IRAK4 deficiency (IRAK4D) [MIM:607676]. IRAK4 deficiency causes extracellular pyogenic bacterial and fungal infections in otherwise healthy children.
    • Sequence similarities
      Belongs to the protein kinase superfamily. TKL Ser/Thr protein kinase family. Pelle subfamily.
      Contains 1 death domain.
      Contains 1 protein kinase domain.
    • Information by UniProt
    • Database links
    • Alternative names
      • IL-1 receptor-associated kinase 4 antibody
      • Interleukin 1 receptor associated kinase 4 mutant form 1 antibody
      • Interleukin-1 receptor-associated kinase 4 antibody
      • Interleukin1 receptor associated kinase 4 antibody
      • IPD1 antibody
      • IRAK 4 antibody
      • IRAK-4 antibody
      • IRAK4 antibody
      • IRAK4 mutated form 1 antibody
      • IRAK4_HUMAN antibody
      • LOC 51135 antibody
      • NY REN 64 antibody
      • NY REN 64 antigen antibody
      • NY-REN-64 antibody
      • REN64 antibody
      • Renal carcinoma antigen NY-REN-64 antibody
      see all


    • IHC image of ab32511 staining in human spleen formalin fixed paraffin embedded tissue section, performed on a Leica Bond system using the standard protocol F. The section was pre-treated using heat mediated antigen retrieval with sodium citrate buffer (pH6, epitope retrieval solution 1) for 20 mins. The section was then incubated with ab32511, 1µg/ml, for 15 mins at room temperature and detected using an HRP conjugated compact polymer system. DAB was used as the chromogen. The section was then counterstained with haematoxylin and mounted with DPX.

      For other IHC staining systems (automated and non-automated) customers should optimize variable parameters such as antigen retrieval conditions, primary antibody concentration and antibody incubation times.

    • Immunocytochemistry/Immunofluorescence analysis of Jurkat (Human T cell leukemia cell line from peripheral blood) cells labeling IRAK4 with ab32511 at 1/100 dilution. Cells were fixed with 100% methanol. ab150077, an AlexaFluor® 488 conjugated goat anti-rabbit IgG (1/1000) was used as the secondary antibody. The cells were co-stained with ab195889, anti-alpha tubulin antibody [DM1A] - Microtubule Marker (Alexa Fluor® 594) at 1/200 dilution. Nuclei counterstained with DAPI (blue). 


    • Anti-IRAK4 antibody [Y279] (ab32511) at 1/500 dilution + Jurkat cell lysate

      Observed band size: 52 kDa (why is the actual band size different from the predicted?)

    • Flow Cytometry analysis of Jurkat (human acute T cell leukemia) cells labeling IRAK4 with purified ab32511 at 1/110 dilution (10ug/ml) (red). Cells were fixed with 4% paraformaldehyde and permeabilised with 90% methanol. A Goat anti rabbit IgG (Alexa Fluor® 488)(1/2000 dilution) was used as the secondary antibody. Rabbit monoclonal IgG (Black) was used as the isotype control, cells without incubation with primary antibody and secondary antibody (Blue) was used as the unlabeled control.


    This product has been referenced in:
    • Sun J  et al. Comprehensive RNAi-based screening of human and mouse TLR pathways identifies species-specific preferences in signaling protein use. Sci Signal 9:ra3 (2016). Read more (PubMed: 26732763) »

    See 1 Publication for this product

    Customer reviews and Q&As

    There are currently no Customer reviews or Questions for ab32511.
    Please use the links above to contact us or submit feedback about this product.


    Sign up